The New England journal of medicine, 2019-10, Vol.381 (18), p.1728-1740
- Perl, Alexander E
- Martinelli, Giovanni
- Cortes, Jorge E
- Neubauer, Andreas
- Berman, Ellin
- Paolini, Stefania
- Montesinos, Pau
- Baer, Maria R
- Larson, Richard A
- Ustun, Celalettin
- Fabbiano, Francesco
- Erba, Harry P
- Di Stasi, Antonio
- Stuart, Robert
- Olin, Rebecca
- Kasner, Margaret
- Ciceri, Fabio
- Chou, Wen-Chien
- Podoltsev, Nikolai
- Recher, Christian
- Yokoyama, Hisayuki
- Hosono, Naoko
- Yoon, Sung-Soo
- Lee, Je-Hwan
- Pardee, Timothy
- Fathi, Amir T
- Liu, Chaofeng
- Hasabou, Nahla
- Liu, Xuan
- Bahceci, Erkut
- Levis, Mark J
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Perl, Alexander E
- Martinelli, Giovanni
- Cortes, Jorge E
- Neubauer, Andreas
- Berman, Ellin
- Paolini, Stefania
- Montesinos, Pau
- Baer, Maria R
- Larson, Richard A
- Ustun, Celalettin
- Fabbiano, Francesco
- Erba, Harry P
- Di Stasi, Antonio
- Stuart, Robert
- Olin, Rebecca
- Kasner, Margaret
- Ciceri, Fabio
- Chou, Wen-Chien
- Podoltsev, Nikolai
- Recher, Christian
- Yokoyama, Hisayuki
- Hosono, Naoko
- Yoon, Sung-Soo
- Lee, Je-Hwan
- Pardee, Timothy
- Fathi, Amir T
- Liu, Chaofeng
- Hasabou, Nahla
- Liu, Xuan
- Bahceci, Erkut
- Levis, Mark J
- Titel
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- Ist Teil von
- The New England journal of medicine, 2019-10, Vol.381 (18), p.1728-1740
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Oral use of the selective FLT3 kinase inhibitor gilteritinib in patients who had relapsed or refractory acute myeloid leukemia with FLT3 mutations led to a median overall survival of 9.3 months (vs. 5.6 months with standard chemotherapy) and complete remission with full or partial hematologic recovery in 34.0% of patients (vs. 15.3%).
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1902688Titel-ID: cdi_proquest_journals_2310710163
- Format
- –
- Schlagworte
- Acute myeloid leukemia, Administration, Oral, Adult, Aged, Aged, 80 and over, Aniline Compounds - adverse effects, Aniline Compounds - therapeutic use, Antineoplastic Agents - adverse effects, Antineoplastic Agents - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Chemotherapy, Death, Drug Resistance, Neoplasm, Female, Flt3 protein, fms-Like Tyrosine Kinase 3 - genetics, Follow-Up Studies, Humans, Laboratories, Leukemia, Myeloid, Acute - drug therapy, Leukemia, Myeloid, Acute - genetics, Leukemia, Myeloid, Acute - mortality, Liver - drug effects, Male, Medical prognosis, Middle Aged, Mutation, Myeloid leukemia, Neutropenia, Pharmaceuticals, Protein-tyrosine kinase, Pyrazines - adverse effects, Pyrazines - therapeutic use, Recurrence, Remission, Remission (Medicine), Remission Induction, Salvage Therapy, Survival, Survival Analysis, Thrombocytopenia